Management of advanced non-small cell lung cancers with known mutations or rearrangements: Latest evidence and treatment approaches

Therapeutic Advances in Respiratory Disease

Volumn 10, Issue 2, 2016, Pages 113-129

  Shea, Meghan ^a   Costa, Daniel B ^a   Rangachari, Deepa ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

adenocarcinoma; anaplastic lymphoma kinase (ALK); c ros oncogene 1 (ROS1); epidermal growth factor (EGFR); mesenchymal epithelial transition factor proto oncogene (MET); non small cell lung cancer; precision oncology; raf murine sarcoma viral oncogene homolog B1 (BRAF); rearranged during transfection (RET); targeted therapies

Indexed keywords

AFATINIB; ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; BRIGATINIB; CABOZANTINIB; CARBOPLATIN; CERITINIB; CETUXIMAB; CISPLATIN; CRIZOTINIB; DABRAFENIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; LENVATINIB; OSIMERTINIB; PACLITAXEL; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; ROCILETINIB; SCATTER FACTOR RECEPTOR; TRAMETINIB; TRASTUZUMAB; VANDETANIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ACNE; ADVANCED CANCER; ANOREXIA; CANCER PALLIATIVE THERAPY; CANCER RESISTANCE; CENTRAL NERVOUS SYSTEM METASTASIS; CHROMOSOME REARRANGEMENT; CONSTIPATION; COUGHING; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; FATIGUE; FEVER; GENE AMPLIFICATION; GENE MUTATION; GENE REARRANGEMENT; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPONATREMIA; LIVER DYSFUNCTION; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOMA; LUNG FIBROSIS; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE; ONCOGENE K RAS; OVERALL SURVIVAL; PARONYCHIA; PERIPHERAL EDEMA; PHARMACOGENETICS; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTO ONCOGENE; RASH; REVIEW; SQUAMOUS CELL LUNG CARCINOMA; THROMBOCYTOPENIA; VISUAL IMPAIRMENT; VOMITING; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION; GENETICS; LUNG NEOPLASMS; MUTATION; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PHENOTYPE; PREDICTIVE VALUE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; DNA MUTATIONAL ANALYSIS; GENE REARRANGEMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; PATIENT SELECTION; PHENOTYPE; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84960496176     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465815617871     Document Type: Review

References (99)

1. Awad M., Katayama R., McTigue M., Liu W., Deng Y., Brooun A., et al. (2013) Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 368: 2395-2401.
2. Baik C., Chamberlain M., Chow L., (2015) Targeted therapy for brain metastases in EGFR-mutated and ALK-rearranged non-small-cell lung cancer. J Thorac Oncol 10: 1268-1278.
3. Bauer T., Solomon B., Besse B., Navarro B., James L, Clancy J., et al. (2015) Clinical activity and safety of the ALK/ROS1 TK inhibitor PF-06463922 in advanced NSCLC. J Thorac Oncol 10 (2 Suppl): 33.07 (abstract, oral).
4. Brunner A., Costa D., Heist R., Garcia E., Lindeman N., Sholl L., et al. (2013) Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung. J Thorac Oncol 8: 1434-1437.
5. Buttitta F., Barassi F., Fresu G., Felicioni L., Chella A., Paolizzi D., et al. (2006) Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer 119: 2586-2591.
6. Camidge D., Bang Y., Kwak E., Iafrate A., Varella-Garcia M., Fox S., et al. (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13: 1011-1019.
7. Camidge D., Ou I., Shapiro G., Otterson G., Cosca Villaruz L., Villalona-Calero M., et al. (2014) Efficacy and safety of crizotinib in patients with advanced c-MET amplified non-small cell lung cancer (NSCLC). J Clin Oncol 32 (5 Suppl.): 8001 (abstract).
8. Cancer Genome Atlas Research Network (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511: 543-550.
9. Chaft J., Oxnard G., Sima C., Kris M., Miller V., Riely G., (2011) Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 17: 6298-6303.
10. Chin L., Soo R., Soong R., Ou S., (2012) Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. J Thorac Oncol 7: 1625-1630.
11. Chong C., Janne P., (2013) The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 19: 1389-1400.
12. Costa D., Halmos B., Kumar A., Schumer S., Huberman M., Boggon T., et al. (2007) BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 4: 1669-1679; discussion 1680.
13. Costa D., Kobayashi S., Pandya S., Yeo W., Shen Z., Tan W., et al. 2011. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 29: e443-e445.
14. Costa D., Shaw A., Ou S., Solomon B., Riely G., Ahn M., et al. (2015) Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 33: 1881-1888.
15. De Greve J., Teugels E., Geers C., Decoster L., Galdermans D., De Mey J., et al. (2012) Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 76: 123-127.
16. Doebele R., Pilling A., Aisner D., Kutateladze T., Le A., Weickhardt A., et al. (2012) Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 18: 1472-1482.
17. Drilon A., Wang L., Hasanovic A., Suehara Y., Lipson D., Stephens P., et al. (2013) Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 3: 630-635.
18. Drilon A., Sima C., Somwar R., Smith R., Ginsberg M., Riely G., et al. (2015) Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers. ASCO Meeting Abstracts. J Clin Oncol 33: 8007 (abstract).
19. Dutt A., Ramos A., Hammerman P., Mermel C., Cho J., Sharifnia T., et al. (2011) Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 6: e20351.
20. Eng J., Bob T., Hsu M., Chaft J., Arcila M., Kris M., (2015) Outcomes with chemotherapies and molecular characteristics of HER2-mutant lung cancers. ASCO Meeting Abstracts. J Clin Oncol 33: 8068 (abstract).
21. Frampton G., Ali S., Rosenzweig M., Chmielecki J., Lu X., Bauer T., et al. (2015) Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 5: 850-859.
22. Gadgeel S., Gandhi L., Riely G., Chiappori A., West H., Azada M., et al. (2014) Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 15: 1119-1128.
23. Gatzemeier U., Groth G., Butts C., Van Zandwijk N., Shepherd F., Ardizzoni A., et al. (2004) Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 15: 19-27.
24. Gautschi O., Zander T., Keller F., Strobel K., Hirschmann A., Aebi S., et al. (2013) A patient with lung adenocarcinoma and RET fusion treated with vandetanib. J Thorac Oncol 8: e43-e44.
25. Gerber D., Gandhi L., Costa D., (2014) Management and Future Directions in Non-Small Cell Lung Cancer with Known Activating Mutations. Chicago, IL: ASCO Educational Book.
26. Goldman J., Gray J., (2015) BRAF V600E mutations: a series of case reports in patients with non-small cell lung cancer. Cancer Genet 208: 351-354.
27. Hammerman P., Sos M., Ramos A., Xu C., Dutt A., Zhou W., et al. (2011) Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 1: 78-89.
28. Haura E., Tanvetyanon T., Chiappori A., Williams C., Simon G., Antonia S., et al. (2010) Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 28: 1387-1394.
29. Horn L., Jeffrey R., Blumenschein G., Wakelee H., Arkenau H., Dukart G., et al. (2014) A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. J Clin Oncol 32 (5 Suppl.): 8030 (abstract).
30. Janjigian Y., Smit E., Groen H., Horn L., Gettinger S., Camidge D., et al. (2014) Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov 4: 1036-1045.
31. Janne P., Shaw A., Pereira J., Jeannin G., Vansteenkiste J., Barrios C., et al. (2013) Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 14: 38-47.
32. Janne P., Yang J., Kim D., Planchard D., Ohe Y., Ramalingam S., et al. (2015) AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372: 1689-1699.
33. Jorge S., Kobayashi S., Costa D., (2014) Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. Braz J Med Biol Res 47: 929-939.
34. Ju Y., Lee W., Shin J., Lee S., Bleazard T., Won J., et al. (2012) A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 22: 436-445.
35. Keedy V., Temin S., Somerfield M., Beasley M., Johnson D., McShane L., et al. (2011) American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29: 2121-2127.
36. Kim Y., Hammerman P., Kim J., Yoon J., Lee Y., Sun J., et al. (2014) Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol 32: 121-128.
37. Kobayashi S., Boggon T., Dayaram T., Janne P., Kocher O., Meyerson M., et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792.
38. Kohno T., Ichikawa H., Totoki Y., Yasuda K., Hiramoto M., Nammo T., et al. (2012) KIF5B-RET fusions in lung adenocarcinoma. Nat Med 18: 375-377.
39. Kollmannsberger C., Sharma S., Shapiro G., Chi K., Christensen J., Roberts Tassell V., et al. (2015) Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors. J Clin Oncol 33: 2589 (abstract).
40. Kong-Beltran M., Seshagiri S., Zha J., Zhu W., Bhawe K., Mendoza N., et al. (2006) Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 66: 283-289.
41. Kris M., Johnson B., Berry L., Kwiatkowski D., Iafrate A., Wistuba I., et al. (2014) Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311: 1998-2006.
42. Kwak E., Bang Y., Camidge D., Shaw A., Solomon B., Maki R., et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703.
43. Langer C., Stephenson P., Thor A., Vangel M., Johnson D., (2004) Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol 22: 1180-1187.
44. Li B., Ross D.S., Chaft J., Kako S., Aisner D., Kris M., et al. (2015) Defining the spectrum and 'overlap' of HER2 aberrations in lung cancers: Associations of HER2 protein overexpression, HER2 amplification and HER2 mutation. ASCO Meeting Abstracts. J Clin Oncol 33: 8067 (abstract).
45. Li C., Fang R., Sun Y., Han X., Li F., Gao B., et al. (2011) Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One 6: e28204.
46. Lindeman N., Cagle P., Beasley M., Chitale D., Dacic S., Giaccone G., et al. (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 8: 823-859.
47. Lipson D., Capelletti M., Yelensky R., Otto G., Parker A., Jarosz M., et al. (2012) Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18: 382-384.
48. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388.
49. Marchetti A., Felicioni L., Malatesta S., Grazia Sciarrotta M., Guetti L., Chella A., et al. (2011) Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 29: 3574-3579.
50. Matsubara D., Kanai Y., Ishikawa S., Ohara S., Yoshimoto T., Sakatani T., et al. (2012) Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad. J Thorac Oncol 7: 1872-1876.
51. Mazieres J., Peters S., Lepage B., Cortot A., Barlesi F., Beau-Faller M., et al. (2013) Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 31: 1997-2003.
52. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128.
53. Mok T., Wu Y., Thongprasert S., Yang C., Chu D., Saijo N., et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957.
54. Mologni L., Ceccon M., Pirola A., Chiriano G., Piazza R., Scapozza L., et al. (2015) NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922. Oncotarget 6: 5720-5734.
55. Mologni L., Redaelli S., Morandi A., Plaza-Menacho I., Gambacorti-Passerini C., (2013) Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase. Mol Cell Endocrinol 377: 1-6.
56. Morgensztern D., Campo M., Dahlberg S., Doebele R., Garon E., Gerber D., et al. (2015) Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 10: S1-S63.
57. Moro-Sibilot D., Faivre L., Zalcman G., Perol M., Barlesi F., Otto J., et al. (2015) Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of ACSe phase II trial. J Clin Oncol 33 (Suppl.): abstract 8065.
58. National Comprehensive Cancer Network (2015) NCCN Clinical Practice Guidelines [Online]. Available at: http://www.nccn.org/ (. accessed 15 July 2015).
59. Nguyen K., Kobayashi S., Costa D., (2009) Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 10: 281-289.
60. Okamoto K., Kodama K., Takase K., Sugi N., Yamamoto Y., Iwata M., et al. (2013) Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett 340: 97-103.
61. Paik P., Drilon A.E., Yu H., Krug L., Rekhtman N., Borsu L., et al. (2015) Response to crizotinib and cabozantinib in stage IV lung adenocarcinoma patients with mutations that cause MET exon 14 skipping. ASCO Meeting Abstracts. J Clin Oncol 33: 8021 (abstract).
62. Park S., Choi Y., Sung C., An J., Seo J., Ahn M., et al. (2012) High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histol Histopathol 27: 197-207.
63. Planchard D., Groen H.J.M., Kim T., Rigas J., Souquet P., Baik C., et al. (2015) Interim results of a phase II study of BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts. J Clin Oncol 33: 8006 (abstract).
64. Planchard D., O'Shaughnessy J.A., Cowey C., Konduri K., (2013) Interim results of phase II study BRF 113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients. ASCO Meeting Abstracts. J Clin Oncol 31: 8009 (abstract).
65. Rangachari D., Yamaguchi N., Vanderlaan P., Folch E., Mahadevan A., Floyd S., et al. (2015) Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 88: 108-111.
66. Robinson S., O'Shaughnessy J., Cowey C., Konduri K., (2014) BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. Lung Cancer 85: 326-330.
67. Rodenhuis S., Slebos R., (1992) Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 52: 2665s-2669s.
68. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239-246.
69. Sacher A., Sholl L.M., Mach S., Johnson B., Hammerman P., Janne P., et al. (2015) Feasibility of next-generation sequencing (NGS) for squamous non-small cell lung cancer (NSCLC): implications for the NCI LungMAP study. ASCO meeting abstracts. J Clin Oncol 33: 8096 (abstract).
70. Saito M., Ishigame T., Tsuta K., Kumamoto K., Imai T., Kohno T., (2014) A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis. Carcinogenesis 35: 2452-2456.
71. Schleffer M., Schultheis A.M., Teixido C., Friedrich Michels S., Morales-Espinosa D., Viteri S., et al. (2015) ROS1 rearrangement in non-small cell lung cancer (NSCLC): Prognostic and predictive impact and genetic variability. J Clin Oncol 33 (Suppl.): abstract 8066.
72. Sequist L., Soria J., Goldman J., Wakelee H., Gadgeel S., Varga A., et al. (2015) Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 372: 1700-1709.
73. Sequist L., Waltman B., Dias-Santagata D., Digumarthy S., Turke A., Fidias P., et al. (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3: 75ra26.
74. Sequist L., Yang J., Yamamoto N., O'Byrne K., Hirsh V., Mok T., et al. (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31: 3327-3334.
75. Seto T., Kiura K., Nishio M., Nakagawa K., Maemondo M., Inoue A., et al. (2013) CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 14: 590-598.
76. Shaw A., Kim D., Mehra R., Tan D., Felip E., Chow L., et al. (2014a) Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 370: 1189-1197.
77. Shaw A., Kim D., Nakagawa K., Seto T., Crino L., Ahn M., et al. (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368: 2385-2394.
78. Shaw A., Ou S., Bang Y., Camidge D., Solomon B., Salgia R., et al. (2014b) Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371: 1963-1971.
79. Shaw A., Yeap B., Solomon B., Riely G., Gainor J., Engelman J., et al. (2011) Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12: 1004-1012.
80. Solomon B., Mok T., Kim D., Wu Y., Nakagawa K., Mekhail T., et al. (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371: 2167-2177.
81. Soria J., Wu Y., Nakagawa K., Kim S., Yang J., Ahn M., et al. (2015) Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol 16: 990-998.
82. Suzuki M., Makinoshima H., Matsumoto S., Suzuki A., Mimaki S., Matsushima K., et al. (2013) Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo. Cancer Sci 104: 896-903.
83. Takeuchi K., Soda M., Togashi Y., Suzuki R., Sakata S., Hatano S., et al. (2012) RET, ROS1 and ALK fusions in lung cancer. Nat Med 18: 378-381.
84. Tucker J., Klein T., Breed J., Breeze A., Overman R., Phillips C., et al. (2014) Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4. Structure 22: 1764-1774.
85. Weickhardt A., Scheier B., Burke J., Gan G., Lu X., Bunn P., et al. (2012) Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 7: 1807-1814.
86. Wu Y., Zhou C., Hu C., Feng J., Lu S., Huang Y., et al. (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15: 213-222.
87. Yamaguchi N., Lucena-Araujo A., Nakayama S., De Figueiredo-Pontes L., Gonzalez D., Yasuda H., et al. (2014) Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. Lung Cancer 83: 37-43.
88. Yang J., Hirsh V., Schuler M., Yamamoto N., O'Byrne K., Mok T., et al. (2013) Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 31: 3342-3350.
89. Yasuda H., De Figueiredo-Pontes L., Kobayashi S., Costa D., (2012a) Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol 7: 1086-1090.
90. Yasuda H., Kobayashi S., Costa D., (2012b) EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol 13: e23-e31.
91. Yasuda H., Park E., Yun C., Sng N., Lucena-Araujo A., Yeo W., et al. (2013) Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med 5: 216ra177.
92. Yeo W., Riely G., Yeap B., Lau M., Warner J., Bodio K., et al. (2010) Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol 5: 1048-1053.
93. Yu H., Arcila M., Rekhtman N., Sima C., Zakowski M., Pao W., et al. (2013a) Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19: 2240-2247.
94. Yu H., Sima C., Huang J., Solomon S., Rimner A., Paik P., et al. (2013b) Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol 8: 346-351.
95. Zhao H., Fan Y., Ma S., Song X., Han B., Cheng Y., et al. (2015) Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804). J Thorac Oncol 10: 655-664.
96. Zheng Z., Liebers M., Zhelyazkova B., Cao Y., Panditi D., Lynch K., et al. (2014) Anchored multiplex PCR for targeted next-generation sequencing. Nat Med 20: 1479-1484.
97. Zhou C., Wu Y., Chen G., Feng J., Liu X., Wang C., et al. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735-742.
98. Zou H., Friboulet L., Kodack D., Engstrom L., Li Q., West M., et al. (2015a) PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell 28: 70-81.
99. Zou H., Li Q., Engstrom L., West M., Appleman V., Wong K., et al. (2015b) PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci U S A 112: 3493-3498.